Recombinant Anti-IL-17A antibody [EPR21776] (ab218013)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR21776] to IL-17A
- Suitable for: WB
- Reacts with: Mouse
Related conjugates and formulations
Overview
-
Product name
Anti-IL-17A antibody [EPR21776]
See all IL-17A primary antibodies -
Description
Rabbit monoclonal [EPR21776] to IL-17A -
Host species
Rabbit -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Mouse -
Immunogen
Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: EL4 cells treated with PMA, ionomycin (ab120116) and Brefeldin A, whole cell lysate.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR21776 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab218013 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000. Detects a band of approximately 14,17 kDa (predicted molecular weight: 17 kDa).
|
Notes |
---|
WB
1/1000. Detects a band of approximately 14,17 kDa (predicted molecular weight: 17 kDa). |
Target
-
Function
Induces stromal cells to produce proinflammatory and hematopoietic cytokines. Enhances the surface expression of the intracellular adhesion molecule-1 (ICAM-1) in fibroblasts. -
Tissue specificity
Restricted to activated memory T-cells. -
Sequence similarities
Belongs to the IL-17 family. -
Post-translational
modificationsFound both in glycosylated and nonglycosylated forms. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 16171 Mouse
- SwissProt: Q62386 Mouse
-
Alternative names
- CTLA 8 antibody
- CTLA-8 antibody
- CTLA8 antibody
see all
Images
-
All lanes : Anti-IL-17A antibody [EPR21776] (ab218013) at 1/1000 dilution
Lane 1 : Untreated EL4 (mouse lymphoma T lymphocyte) whole cell lysate
Lane 2 : EL4 treated with 50 ng/ml Phorbol-12-myristate-13-acetate (PMA) and 500 ng/ml ionomycin (ab120116) for 6 hours, then with 500 ng/ml Brefeldin A for 18 hours, whole cell lysate
Lysates/proteins at 10 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution
Developed using the ECL technique.
Predicted band size: 17 kDa
Observed band size: 14,17 kDa why is the actual band size different from the predicted?
Exposure time: 3 minutesBlocking/dilution buffer and concentration: 5% NFDM/TBST
Expression of IL-17A can be induced by PMA and Ionomycin treatment (PMID 28382171).
The expression profile is consistent with the literature (PMID 9764847).
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (1)
ab218013 has been referenced in 1 publication.
- Peng S et al. Recombinant programmed cell death 1 inhibits psoriatic inflammation in imiquimod-treated mice. Int J Mol Med 46:869-879 (2020). PubMed: 32468061